Characteristic,Net present value in billion U.S. dollars
Ide-Cel (acquired),6.2
Risdiplam (in-licensed),5.3
Valoctocogene Roxaparvovec  (in-licensed),5.1
Efgartigimod (organic),4.3
Liso-Cel  (acquired),4.2
Selpercatinib (acquired),4.1
Belantamab Mafodotin  (organic),3.8
Ripretinib  (organic),3.1
Tafasitamab (in-licensed),2.8
Lenabasum (in-licensed),2.7
